

## Anti-Malaria Quality Control Reagent Sample 1

Anti-Malaria QC1

### SUMMARY

Human anti-Malaria Quality Control Reagent Sample 1 (**Anti-Malaria QC1** Lot Number **06/B475**) is issued in 4mL volumes.

### INTENDED USE

Anti-Malaria QC1 is intended for use in the internal laboratory quality control of immunoassays that detect antibodies to *Plasmodium falciparum*. The Anti-Malaria QC1 should be included in each run as part of a continuing quality control programme to monitor the performance of the assay. Data obtained with the Anti-Malaria QC1 can be used to construct quality control charts that can be visually monitored each time the assay is carried out to check for consistency of performance of the assay. Examples of how these charts are constructed and used have been described elsewhere<sup>1</sup>. Anti-Malaria QC1 is NOT INTENDED TO BE USED TO COMPARE THE SENSITIVITY OF PARTICULAR ASSAYS.

### CONTENT OF THE KIT

REF QCRMALQC1	Ready-to-use reagent 1x4mL Nalgene bottle
---------------	--

### COMPOSITION

Defibrinated Plasma	4mL
Bronidox <sup>®</sup> (Sigma-Aldrich)	0.05% (w/v)

### MATERIALS REQUIRED BUT NOT PROVIDED

- Micropipette for dispensing

### WARNINGS AND PRECAUTIONS

This reagent is for *in-vitro* use only.

As this reagent contains material of human origin, it is possible that infectious agents could be present and therefore this reagent, waste washing fluids, and any apparatus (pipette tips etc.) that come into contact with it, must be suitably decontaminated and handled in accordance with Good Laboratory Practice.

### TRANSPORT INFORMATION

Shipping Name	Diagnostic Specimen
Class/Division	6.2
UN	3373
Packaging Instruction	PI-650

### PREPARATION

The Anti-Malaria QC1 has been prepared from a pool of anti-*P.falciparum* reactive defibrinated plasma donations, repeatedly reactive in commercial EIA kits. The reactive donations used to prepare Anti-Malaria QC1 were non-reactive for anti-HIV, HBsAg and anti-HCV using commercial EIA kits. The reactive sera were pooled and then diluted in a pool of defibrinated human plasma donations non-reactive for anti-*P.falciparum*. These samples were also non-reactive for HBsAg, anti-HCV and anti-HIV using commercial EIA kits. Bronidox<sup>®</sup> was added to a concentration of 0.05%(w/v) as a preservative.

### SUMMARY OF RESULTS OBTAINED

**Table 1** gives a summary of the results obtained for Anti-Malaria QC1 **06/B475**. These results are intended only as a guide to the approximate levels of reactivity to be expected, and may not be exactly reproduced in other laboratories. In each case, at a minimum, three samples of Anti-Malaria QC1 were tested on two occasions. The results are expressed as the ratio of mean optical density or other measurement of the Anti-Malaria response to the QC1 sample, to the kit manufacturer's calculated cut-off.

### INSTRUCTIONS FOR USE

1. Use of this reagent is to be restricted to trained laboratory staff only
2. Use suitable (latex/nitrile) gloves and eye/skin protection
3. Include reagent as a normal sample in routine work list
4. Allow reagent to reach room temperature before use
5. Plot reagent result on a QC chart to monitor performance.

### HANDLING AND STORAGE CONDITIONS

- Avoid contact with skin and eyes
- Reagents are to be kept at 2-8°C upon receipt
- Reagents may be stored at 2-8°C until use by date
- Reagents should be divided into measured sub-aliquots of one use and stored below -20°C to avoid freeze/thaw cycles
- When thawed for use, store at 2-8°C. Once thawed, use within one month and do not refreeze
- Ensure all containers are properly sealed to avoid drying out of the reagent
- Avoid microbial contamination of this product as this may alter product performance
- Avoid excessively high temperatures or humidity

# REF QCRMALQC1

## DISPOSAL CONSIDERATIONS

It is the responsibility of each user to handle waste and effluents produced according to their type and degree of hazard and to treat and dispose of them in accordance with any applicable regulations.

Treat this reagent as clinical waste and dispose of according to clinical waste policies in place.

## ACCIDENTAL RELEASE MEASURES

In the event of a spill or leakage, wear suitable eye/skin protection. Use absorbent material to soak up spill. Wipe area with appropriate bactericidal/viricidal agent. Rinse area with water.

**Treat all absorbent material used to clean up spill as biological hazardous waste.**

## LITERATURE REFERENCES

1. Levey, S. and Jennings, E.R. (1950) The use of control charts in clinical laboratories. Am.J.Clin.Pathol. 20, 1059-1066

**TABLE 1:** Results obtained for **Anti-Malaria QC1** (Lot Number **06/B475**) using the following EIA kits.

EIA KIT	Method Options	Test to Cut-off Ratio	
		Mean	SD (n-1)
<b>Newmarket Malaria EIA 96*</b> Manufacturer: Newmarket Catalogue number: 60089 Lot number: 610901, 615006 & 532101	Standard Protocol	4.26	0.60

\*Some tests performed at NBS Colindale